Newron Pharmaceuticals S.p.A. (NWPHF)
OTCMKTS · Delayed Price · Currency is USD
12.00
+0.60 (5.26%)
May 15, 2024, 8:30 AM EST
Newron Pharmaceuticals Employees
Newron Pharmaceuticals had 22 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
22
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,196,552
Profits / Employee
$1,351,999
Market Cap
506.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 22 | 0 | - |
| Dec 31, 2023 | 22 | -1 | -4.35% |
| Dec 31, 2022 | 23 | -2 | -8.00% |
| Dec 31, 2021 | 25 | 2 | 8.70% |
| Dec 31, 2020 | 23 | -3 | -11.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
Newron Pharmaceuticals News
- 9 days ago - Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia - Business Wire
- 5 weeks ago - EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - Business Wire
- 5 weeks ago - Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent - Business Wire
- 7 weeks ago - Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week - Business Wire
- 2 months ago - Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS) - Business Wire
- 4 months ago - Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025 - Business Wire
- 5 months ago - Newron presents H1 2025 results and provides business update - Business Wire
- 5 months ago - Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP) - Business Wire